Tx Medic Ab

Other

Astrazeneca Ab

Corline Systems Ab

Tikomed Ab

Allvivo, Inc.

Icoat Medical Ab

Bo Nilsson

Olle Korsgren

Jennifer A Neff

Karin Caldwell

Jonas Andersson

Kristina Nilsson-Ekdahl

Lars M Bruce

Rolf Larsson

Adam Bruce

Wade Akira Takeguchi

William Bennet

Hangkan Dahlberg

Karin D Caldwell

Kristina Nilsson Ekdahl

Marianne Jensen Waern

Alireza Biglarnia

Yuji Teramura

A graft composition intended for transplantation into a human patient comprises an injection solution comprising an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 Da.

Use of dextran sulfate

Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected Dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating T-lymphocytes to treat metastatic cancer in a subject.

Methods for reducing pulmonary uptake of intravenously injected cells

A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.

The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.

Method of treating graft-rejection using dextran sulfate

A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient. The dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 20,000 Da and an average sulphur content in a range of 10 to 25%, and the inhibition comprises administering said therapeutically effective amount of said dextran sulfate, or said pharmaceutically acceptable salt thereof, resulting in a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in the blood of said patient of less than 5 mg/ml.

Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.

Medical device with surface coating comprising bioactive compound

The present invention is within the field of transplantation surgery. More closely, the present invention relates to use of a clotting preventing agent in the production of a drug for administration in association with transplantation of insulin producing cells in the form of isolated islets to patients with insulin dependent diabetes mellitus, IDDM. The invention is expected to significantly improve the clinical outcome of transplantation of islets of Langerhans.

Use within transplantation surgery

A bioartificial implant comprises a semipermeable barrier designed from one side to allow diffusion or prevent diffusion of predetermined substances/materials/molecules/cells/cell lines produced in the human body to the other opposite side of the barrier, and from said other opposite side to allow diffusion or prevent diffusion of predetermined substances which are the same as or different from the first mentioned substances/materials/molecules/cells/cell lines. The semipermeable barrier has a surface coating at least on said one side a bioactive metal, such as titanium, which surface coating is permeable to allow said diffusions. In a method for reducing the risk of formation/growth of connective tissue in connection with an implant which comprises a semipermeable barrier, the barrier is provided at least on one side with a permeable coating of bioactive metal. An example of the use of the implant is bioartificial pancreas.

Bioartificial implant and its use and method of reducing the risk for formation of connective tissue after implantation

Elutable coatings comprising protein resistant components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved under controlled conditions.

Elutable surface coating

Surface coating comprising bioactive compound

According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes.

Use of melagatran for the manufacture of a medicament for the treatment of Type 1 diabetes mellitus

A method to improve the high output characteristics of a ultrasonic transducer 1 by urging a cooling gas 13 to flow through the transducer, thereby passing a cooling member 18 between at least one pair of adjacent piezoelectric elements 6, 7. In a preferred embodiment sulfurhexafluoride (SF.sub.6) is used as cooling gas.

Growing community of inventors

Uppsala, Sweden

Bo Nilsson